Phase 2/3 trial of BMS-986504, a selective MTA-cooperative PRMT5 inhibitor in metastatic NSCLC

This randomized study compares BMS-986504 combined with pembrolizumab and chemotherapy versus placebo regimens in first-line metastatic non-small cell lung cancer patients with homozygous MTAP deletion. BMS-986504 acts as a selective MTA-cooperative PRMT5 inhibitor, and pembrolizumab is a PD-1 inhibitor, with chemotherapy including cisplatin, carboplatin, pemetrexed, paclitaxel, and nab-paclitaxel. Sponsored by Bristol-Myers Squibb, the trial explores a targeted approach in a defined genetic subset.